Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 6/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6021022 | 0.88 | STING1 (0.49) | STING1ALDH1A1KDM4EPDE4BDYRK1A | |
| SCHEMBL6020839 | 0.85 | STING1 (0.47) | STING1ALDH1A1KDM4ETDP1PDE4B | |
| SCHEMBL6021329 | 0.85 | STING1 (0.47) | STING1TDP1PDE4BDYRK1AL3MBTL1 | |
| SCHEMBL6021255 | 0.84 | STING1 (0.46) | STING1ALDH1A1KDM4ETDP1PDE4B | |
| SCHEMBL6021540 | 0.84 | STING1 (0.46) | STING1ALDH1A1KDM4ETDP1PDE4B | |
| SCHEMBL6020606 | 0.79 | STING1 (0.44) | STING1SCN9AL3MBTL1 | |
| SCHEMBL6021442 | 0.78 | STING1 (0.46) | STING1ALDH1A1KDM4EPDE4BLMNA | |
| SCHEMBL4762800 | 0.77 | STING1 (0.46) | STING1ALDH1A1KDM4EDYRK1ALMNA | |
| SCHEMBL6026545 | 0.77 | HTR2A (0.41) | STING1SCN9ATDP1DYRK1APLK1 | |
| SCHEMBL4763705 | 0.77 | STING1 (0.41) | STING1ALDH1A1DYRK1AL3MBTL1EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | claimed |
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | claimed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | claimed |
| EP-1636210-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | CONNOLLY MICHAEL KEVIN (US) | 2005-01-27 | — | — | US | claimed |
| WO-2004108713-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | claimed |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | DIACOVO THOMAS G | 2008-11-20 | — | — | US | disclosed |
| EP-1885356-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006089106-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION | ICOS CORPORATION (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1636210-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | CONNOLLY MICHAEL KEVIN (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004108713-A1 | CYCLOALKYL AND HETEROCYCLOALKYL SUBSTITUTED BENZOTHIOPHENES AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020630-A1 | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents | MALT1, CYP1B1, WEE2 | STING1 2586/4885SCN9A 4797/4885ALDH1A1 178/4885 |
| US-20080287469-A1 | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation | PI4KB, PIK3CA, PI4KA | STING1 915/4885SCN9A 3366/4885ALDH1A1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.